ABSTRACT. Thromboxane A2 (TxA2) is an arachidonic PAP, pulmonary arterial pressure acid metabolite which causes severe pulmonary vasocon-LVEDP, left ventricular end diastolic pressure striction (PV) and may mediate the PV produced by platelet-activating factor (PAF-acether) and leukotriene D4 (LTD4). To determine the role of TxAz receptors on PAFacethe;, LTD4, and hypoxia-induced PV, we administered PAF-acether 0.1 nmollkg, the TxA2 analog U-46619 0.2 pg/kg/min, LTD4 3.0 pg/kg, or acute hypoxia (Fio2 = 0.12 for 3 min) before and during the infusion of the selective TxA2 receptor blocker SQ 29 548 50 pg/kg/min or vehicle into 27 open-chest, anesthetized newborn piglets, measuring pulmonary and systemic arterial pressures, cardiac index, and right and left ventricular pressures and dimensions. Mean pulmonary arterial pressure rose and cardiac index fell in response to PAF-acether (14 f 1 to 32 f 2 mm Hg and 91 f 5 to 15 f 5 mL/kg/min, both p < 0.01), U-46619 (11 f 1 to 28 f 2 mm Hg and 93 2 10 to 36 f 9 mL/kg/min, both p < 0.01), and LTD4 (13 f 3 to 22 f 2 mm Hg and 85 f 12 to 29 + 9 mL/kg/min, both p < 0.05). Acute hypoxia increased PAP (12 + 1 to 26 2 2 mm Hg, p < 0.01) but did not alter cardiac index. Infusion of S Q 29 548 prevented PAF-acether and U-46619-induced increases in pulmonary arterial pressure (13 f 1 to 14 f 1 mm Hg and 12 + 1 to 12 f 1 mm Hg) and decreases in cardiac index (70 f 4 to 70 f 3 mL/kg/min and 94 f 14 to 92 + 12 mL/kg/min) but failed to alter the response to LTD4 or hypoxia. Vehicle had no effect. We conclude that TxA2 receptors are not involved in LTD4 or hypoxiainduced PV but play an important role in the PV produced by PAF-acether and U-46619. (Pediatr Res 26:175-179, 1989) Abbreviations LT, cysteinyl leukotrienes PAF-acether, platelet activating factor (l-O-hexadecyl-2-acetyl-sn-glyceryl phosphocholine) PV, pulmonary vasoconstriction Tx, thromboxane 6-k-PGFI,, 6-keto-prostaglandin F1, SVRI, systematic vascular resistance index MAP, mean systemic arterial pressure RVEDP, right ventricular end-diastolic pressure PVRI, pulmonary vascular resistance index
pg/kg/min, LTD4 3.0 pg/kg, or acute hypoxia (Fio2 = 0.12 for 3 min) before and during the infusion of the selective TxA2 receptor blocker SQ 29 548 50 pg/kg/min or vehicle into 27 open-chest, anesthetized newborn piglets, measuring pulmonary and systemic arterial pressures, cardiac index, and right and left ventricular pressures and dimensions. Mean pulmonary arterial pressure rose and cardiac index fell in response to PAF-acether (14 f 1 to 32 f 2 mm Hg and 91 f 5 to 15 f 5 mL/kg/min, both p < 0.01), U-46619 (11 f 1 to 28 f 2 mm Hg and 93 2 10 to 36 f 9 mL/kg/min, both p < 0.01), and LTD4 (13 f 3 to 22 f 2 mm Hg and 85 f 12 to 29 + 9 mL/kg/min, both p < 0.05). Acute hypoxia increased PAP (12 + 1 to 26 2 2 mm Hg, p < 0.01) but did not alter cardiac index. Infusion of S Q 29 548 prevented PAF-acether and U-46619-induced increases in pulmonary arterial pressure (13 f 1 to 14 f 1 mm Hg and 12 + 1 to 12 f 1 mm Hg) and decreases in cardiac index (70 f 4 to 70 f 3 mL/kg/min and 94 f 14 to 92 + 12 mL/kg/min) but failed to alter the response to LTD4 or hypoxia. Vehicle had no effect. We conclude that TxA2 receptors are not involved in LTD4 or hypoxiainduced PV but play an important role in the PV produced by PAF-acether and U-46619. (Pediatr Res 26:175-179, 1989) Vascular tone in the lung is determined by the local balance of vasodilator and vasoconstrictor influences (1). Arachidonic acid (2, 3) and prostacyclin (4) are involved in the regulation of basal tone in the normal pulmonary circulation; TxA2 (5), PAFacether (6, 7) , and LT (8, 9) have been implicated as mediators of pathophysiologic PV. Released by inflammatory cells, platelets, and vascular endothelium, these membrane lipids appear involved in hypoxic (9-13) and septic (1 4-17) PV in newborns.
TxA2 (and its biologically stable prostaglandin endoperoxide analog, U-466 19) causes marked PV (5) and acts as potent stimuli for platelet aggregation (18) . TxA2 is necessary for pulmonary venous constriction during hypoxia in isolated lamb lungs, but appears not to mediate hypoxic PV alone (19) . TxA2 release accompanies septic (14-1 7) and PAF-acether-induced (20) PV in newborn experimental animals and mediates LT response in sheep but not in cats or pigs (8, 2 1-23). Elevated TxA2 levels are also present in human infants with persistent pulmonary hypertension (24) . Cyclooxygenase and thromboxane synthesis blockade have been shown to attenuate, but not abolish, the pulmonary vasoconstrictor response to group Bp-hemolytic Streptococcus (14, 16) , PAF-acether (20) , and LT (19) . Neither cyclooxygenase nor thromboxane synthetase blockade has been demonstrated to affect U-466 19 induced PV. The development of the highly specific TxA2 receptor antagonist, SQ 29 548 (19, (25) (26) (27) (28) should provide a new means to investigate the role of the TxA2 receptor on pulmonary vasoconstrictor responses. The present study was undertaken to evaluate the selectivity of the blocking effects of SQ 29 548 in the circulation of the newborn pig and to determine the relative contribution of TxA2 to PAFacether, U-466 19, LT, and hypoxia-induced PV.
MATERIALS AND METHODS
Preparation. The hemodynamic effects of PAF-acether, U-46619, leukotriene Dq, and hypoxia were assessed in 27 openchest newborn piglets weighing 2.0-3.9 kg and aged 7-14 d. There were 16 males and 1 1 females.
Animals were sedated with intraperitoneal sodium pentobarbital (10 mg/kg) and anesthetized with intravenous sodium pentobarbital (30 mg/kg). Each animal was intubated with a 3.5-mm outer diameter endotracheal tube and mechanically ventilated with a Harvard animal respirator (Harvard Apparatus Co., Millis, MA) delivering 3 cm Hz0 positive end-expiratory pressure. Inspired oxygen concentration and ventilatory rate were modified at the onset of each experiment to achieve arterial P C O~ between 35 and 45 mm Hg and Po2 between 100 and 200 mm Hg, to prevent any hypoxic component of agonist administration from independently affecting PAP. Polyvinyl catheters were placed in the left external jugular vein and carotid artery and advanced to the superior vena cava and ascending aorta, respectively. A 4 Fr high-fidelity pressure catheter (Millar Instruments, Houston, TX) was directed from the carotid artery to the left ventricle.
A left lateral thoracotomy was performed in the fourth intercostal space. The pericardium was incised along the main pulmonary trunk and the heart suspended in the pencardial cradle. Polyethylene cannulae were inserted into the right ventricle and main pulmonary artery. Since the ductus arteriosus is not patent in this preparation (20) , a calibrated electromagnetic flow transducer (North Carolina Instruments, King, NC) was placed around the main pulmonary artery to measure cardiac output. Two pairs of 1-mm ultrasonic crystals (Dimension 3, Cardiff-bySea, CA) were positioned 10 mm apart and embedded 1-2 mm beneath the anterior epicardial surface of the right and left ventricles. Myocardial segment length was recorded continuously from each region using appropriate signal processing instrumentation (Sonomicrometer 120, Triton Technology, San Diego, CA) and previously described techniques (20 Baseline hemodynamic measurements were taken and determined to be stable for at least 1 h after the surgery in all animals. During the stabilization period, all animals received 0.9% NaCl 10 mL/kg.
Protocol I (n = 13). After base-line arterial blood gas determination and hemodynamic measurements, blood was sampled for levels of TxB2 and 6-k-PGF,,, the stable metabolites of TxA2 and prostacyclin, respectively. Animals then received PAFacether 0.1 nmol/kg intravenous bolus using a standardized 2-s injection technique. This dose of PAF-acether was chosen to produce reversible, near-maximal hemodynamic changes based on previous experiences in our laboratory (20) . All parameters were recorded continuously. One min after PAF-acether injection (peak effect), TxB2 and 6-k-PGF,, levels were repeated. Animals were allowed up to 30 rnin to recover. Baseline parameters were recorded, and piglets were then ventilated with an inspired gas concentration of 12% 0 2 , 88% N2 for 3 min. At 3 min, arterial blood was sampled for pH, Pc02 and PO, measurement. Hypoxia was then discontinued. Next, animals were randomized to receive either SQ 29 548 (SQ), 50 pg/kg/min by contiiluous intravenous infusion (n = 7), or an equal volume of the ethanol containing vehicle (n = 6). The dose of SQ was based on previous in vivo studies that showed maximal antagonistic capacity in dogs, cats, and pigs (25) (26) (27) (28) . Then 30 min later, hypoxia and PAF-acether were given in random order. At the conclusion of the study, animals were given a sodium pentothal overdose and a lethal KC1 injection.
Protocol 2 (n = 10). To confirm the specificity of SQ for the TxA2 receptor in our preparation, a group of six piglets received, in random order, the stable TxA2 analog U-46619, 0.2 pg/kg/ rnin intravenous infusion, and LTD,, 3.0 pg/kg intravenous bolus. The dose of U-466 19 was chosen (based on preliminary data) to approximate the hemodynamic response to PAF-acether (i.e. 250% rise in mean pulmonary arterial pressure); the amount of LTD, was based on previous dose-response studies in our laboratory (29) . Each drug administration was separated by a recovery period of at least 15 min. When circulatory status returned to baseline (2-15 rnin), animals were given the hypoxic challenge as described in group 1. After a 30-min recovery period, SQ infusion was begun. Then 30 min later, administration of U-466 19, LTD4, and hypoxia were repeated.
To determine the eficacy of TxA2 receptor antagonism on the initial exposure to PAF-acether, U-466 19, and hypoxia, a separate group of piglets (n = 4) was given SQ without prior agonist challenge. Baseline hemodynamic measurements were obtained before and 30 min after SQ initiation. Animals then received PAF-acether, U-466 19, and hypoxia, as detailed above, in random order. Protocol 3 (n = 4). To determine the effects of sustained exposure to PAF-acether and to evaluate reversibility of more extended PAF-acether action by TxA2 receptor blockade, four piglets received PAF-acether 0.1 nmol/kg/min by continuous intravenous infusion for 15 min. Animals were allowed a 60-min recovery period. Two animals were assigned to receive SQ and two were given only vehicle, as described above, followed by repeat agonist infusion. One vehicle-treated animal died in the first 60 s of repeat PAF infusion; one experimental animal died shortly after SQ initiation, prior to receiving PAF-acether.
Drugs. Pure synthetic PAF-acether (1-0-hexadecyl-2-acetyl-sn- hept-2-yl]-5-heptanoic acid, generously supplied by Dr. M. Ogletree, Squibb, Princeton, NJ) was prepared by dissolving 15 mg in 2.5 mL of absolute ethanol and stored in the freezer. Solutions for infusion were prepared daily by a 1: 10 dilution of the stock by 2 mM Na2C03 in 0.9% NaCl. TxB2 and 6-k-PGF,, RIA. Blood samples (1.5 mL) were drawn from the external jugular vein, collected into heparinized (100 U/mL) syringes, and immediately decanted into tubes containing a final concentration of indomethacin 20 pM. They were centrifuged for 1 min. The plasma was harvested and frozen at -70°C for later analysis by RIA, as detailed previously (30) .
Data analysis. All data were continuously recorded; those from mid-to end-expiration were chosen for analysis; the respirator was not stopped at any point. Pulmonary flow was assumed to approximate cardiac output (mL/min). CI was calculated as cardiac output/wt (kg); SVRI was calculated as 80 x (MAP -RVEDP)/CI; and the PVRI was calculated as 80 x (PAP -LVEDP)/CI. Ventricular segment lengths and shortening fractions were assessed using standard methods (3 1).
Data are presented as mean values f SEM for the indicated number of piglets. One-way analysis of variance followed by the Student-Newman Keuls test for multiple comparison was used for statistical evaluation. Differences were considered significant when p < 0.05.
RESULTS
Protocol I: effects of PAF-acether before and after SQ or vehicle infusion (Fig. I) . (Fig. 1) returned to base line within 7 min of discontinuation of hypoxia.
Effects of hypoxia before and during SQ or vehicle infusion

E -0
The ratio SVRI/PVRI fell (8 f 2 to 2 f 0, p < 0.01). All other measured parameters were unchanged. Neither SQ nor vehicle infusion altered baseline arterial blood gas content, PAP (1 1 PVRI (7 + 1 to 1 f 0, p < 0.01). LVEDP was unchanged. The pulmonary vasoconstrictor response produced by PAF-acether peaked 15-1 7 s after injection. Circulatory status returned to baseline within 15 min. In the two animals where TxB2 and 6-k-PGF], were measured, TxB2 rose 440% (10 to 54 pg/100 pL and 6-k-PGF,, increased 650% (8 to 60 pg/100 pL). SQ infusion did not alter baseline MAP (6 1 f 5 versus 55 + 4 mm Hg) or PAP (1 3 f 1 versus 13 f 1 mm Hg) when compared to vehicle infusion. There was a slight decrease in baseline CI in the experimental group from 80 f 3 mL/kg/min at the onset of the study to 70 f 4 mL/kg/min with SQ infusion. Similarly, there was a small decrement in base-line CI in vehicle-treated controls from 102 f 8 to 97 f 6 mL/kg/min. Baseline CI was significantly lower in experimental versus control animals both initially (80 f 3 versus 102 f 8 mL/kg/min) and during infusion of SQ (70 f 4 versus 97 f 6), both p < 0.05. TxA2 receptor antagonism with SQ completely inhibited the PAF-acether-induced rise in RVEDP, PAP, and PVRI and fall in CI (Fig. I) . SQ infusion also prevented the PAF-acether-induced decline in right (1 7 f 3 to 1 7 f 3 %) and left ventricular shortening fraction ( 10 % 1 to 10 I 0%). After SQ TxB2 and 6-k-PGFI, levels also rose in response to the second dose of PAF-acether (1 3 to 62 and 13 to Left ventricular shortening fraction and LVEDP did not change.
We have previously reported PAF-acether to be an extremely The peak PAP induced by U-466 19 occurred 1 min after infusion potent pulmonary vasoconstrictor in open-chest, anesthetized was started. PAP decreased to 22 f 3 mm Hg by 5 min after newborn piglets. Recent work from our laboratory also suggested infusion was ended, and returned to baseline levels within 10 + a pivotal role for TxA2 as a mediator of PAF-acether action: 2 min. SQ infusion totally blocked U-466 19-induced PV and the cyclooxygenase blockade with indomethacin attenuated the pulresultant decrement in CI and MAP (Fig. 2) .
monary vasoconstrictor response to PAF-acether; LTDJE, Initial injection of LTD4 ( n = 5) caused significant rises in receptor antagonism had no effect (20) . In contrast, Soifer and PAP (13 + 3 to 22 f 2 mm Hg, p < 0.05), PVRI (9.5 2.9 to Schreiber (32) reported both indomethacin and the LT antago-46.3 + 17.2 dynes s cm-' . kg x p < 0.05), and LVEDP (4 nist, FPL 57231, to decrease PAF-acether-induced pulmonary + 2 to 13 + 5 mm Hg, p < 0.05). CI and left ventricular hypertension in newborn lambs. The dose of PAF-acether chosen shortening fraction fell in response to LTD4 (from 85 + 12 to 29 for the present study, 0.1 nmol/kg (50 ng/kg) was similar to that + 9 mL/kg/min and from 14 f 2 to 4 + 1 %, both p < 0.05). described by other investigators in pigs, dogs, and lambs (7, 32, The circulatory effects of LTD4 peaked at 1 min after injection 33) and produced a comparable rise in PAP and PVRI. Unlike and dissipated in 7 + 1 min. TxA2 receptor antagonism failed to its action in the lamb, PAF-acether injection in our piglets caused attenuate LTD4-induced hemodynamic derangements ( (Fig. 3) . Continuous PAF-ygenase, thromboxane synthetase, prostacyclin synthetase, or acether infusion for 15 min increased PAP to a comparable adenylate cyclase activity in vitro or in vivo (25) . SQ 29 548 has degree as bolus injection (1 3 + 2 to 33 k 2 versus 14 k 2 to 32 been shown to have no effect on systemic concentrations of TxB2 + 2 mm Hg, Fig. 3 ). Interestingly, unlike bolus injection, sus-or 6-k-PGF,, in dogs (26) Results of the present study demonstrate that the pulmonary on the generation of these TxA2 or prostacyclin metabolites in the current study.
Underwood et al. (28) showed that SQ 29 548, 0.5 mg/kg intravenous bolus, eliminated U-466 19-induced bronchoconstriction but failed to block the constrictor airway response to prostaglandins FZa and D2, 5-hydroxytryptamine, metacholine, and histamine (28) . Our study in piglets showed that a similar dose of SQ 29 548 markedly diminished the substantial circulatory actions of PAF-acether and U-46619 while having little effect on the more modest vasoconstrictor responses to LTD4 and hypoxia. We have previously demonstrated that there is no tachyphylaxis to LTD4 in our preparation (29) . Thus, it seems likely that LTD4 action in the piglet is not mediated by TxA2 release. These results contrast to findings in mature sheep, where TxA2 mediates both the pulmonary hemodynamic and lung lymph responses to LTD4 (8, 2 1). The finding that SQ 29 548 not only fails to block, but slightly enhances, the pulmonary pressor response to hypoxia (Fig. 1 ) is interesting and agrees with results in isolated blood-perfused lamb lungs (19) . In the in vitro studies, untreated control lungs demonstrated both arterial and venous constriction during hypoxia; addition of indomethacin, Dazmegrel (a thromboxane synthetase inhibitor) or SQ 29 548 to the perfusate abolished hypoxia-induced pulmonary venous constriction and accentuated pulmonary arterial constriction. The observed enhancement of arterial constriction in vitro was thought to be due to shunting of arachidonic acid preferentially to the lipoxygenase pathway. A similar mechanism should not account for our results: Hammerman et al. (15) in a similar model have shown that TxBz levels do not rise in response to hypoxia alone. Moreover, the TxA2 receptor blocker SQ 29 548 had no inhibitory action on synthesis of cyclooxygenase products.
In conclusion, our results suggest that TxA2 receptor activation is involved in the pulmonary vasoconstrictor response to both PAF-acether and U-466 19, but not to LTD4 and hypoxia. SQ 29 548 may be a useful pharmacologic tool for studying the role of TxA2 in pathophysiologic processes in the circulation of the newborn piglet.
